

## Keynote Lecture from ASCO Past-President

Friday, October 25 16:10~16:30

Room 3 (201+202, 2F, Fukuoka International Congress Center)

Chair : Koji Kono Department of Gastrointestinal Tract Surgery, Fukushima Medical University

### KL-ASCO Updates from ASCO Past President Everett Vokes

ASCO Past President/Medicine, University of Chicago, USA Everett Vokes

## ASCO/JSCO Joint Symposium

Friday, October 25 16:30~18:10

Room 3 (201+202, 2F, Fukuoka International Congress Center)

### Progress of adjuvant therapy after curative surgery

Chair : Koji Kono Department of Gastrointestinal Tract Surgery, Fukushima Medical University

Karyn B. Stitzenberg Surgical Oncology, Surgery, University of North Carolina, USA

#### ASCO-JS-1 Progress of adjuvant therapy after curative surgery

Lung cancer, Oncology, Johns Hopkins University, USA/

Immuno-Oncology, Medicine, Trinity College Dublin, Ireland Patrick Forde

#### ASCO-JS-2 Adjuvant treatment for non-small-cell lung cancer in the new era of immune checkpoint inhibitors and molecular-targeting agents: past, present, and future

Department of Thoracic Surgery, National Cancer Center Hospital

Shun-ichi Watanabe

#### ASCO-JS-3 Using circulating tumor DNA to guide adjuvant decision-making in colorectal cancer: ready for primetime?

Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive

Cancer Center, Georgetown University Medical Center, USA

Benjamin A. Weinberg

#### ASCO-JS-4 Adjuvant chemotherapy for colon cancer: Current Status and Future Perspectives

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital

Atsuo Takashima

#### ASCO-JS-5 Navigating the complexities of evolving treatment options for rectal cancer: How to choose the best option for your patient

Surgical Oncology, Surgery, University of North Carolina, USA

Karyn B. Stitzenberg

## Keynote Lecture from ESMO Past-President

Thursday, October 24 10:40~10:55

Room 3 (201+202, 2F, Fukuoka International Congress Center)

Chair : Takayuki Yoshino Division for the Promotion of Drug and Diagnostic Development,  
Department of Gastrointestinal Oncology, National Cancer Center Hospital East

**KL-ESMO** Nurturing the oncology community together: ESMO  
meets JSCO

Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland Solange Peters

## ESMO/JSCO Joint Symposium

Thursday, October 24 10:55~12:10

Room 3 (201+202, 2F, Fukuoka International Congress Center)

### Precision Oncology, Past, Present and Beyond

Chair : Takayuki Yoshino Division for the Promotion of Drug and Diagnostic Development,  
Department of Gastrointestinal Oncology, National Cancer Center Hospital East

Solange Peters Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland

**ESMO-JS-1** Precision Oncology: the illustration of NSCLC

Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland Solange Peters

**ESMO-JS-2** Precision Oncology based on Comprehensive Genomic  
Profiling Test, Past, Present and Beyond in Japan

Department of Medical Oncology, Graduate School of Medicine, Kyoto University/

Department of Clinical Oncology, Kyoto University Hospital Manabu Muto

**ESMO-JS-3** The Past, Present, and Future of Precision Oncology:  
Leveraging Genetic Biomarkers and ctDNA for Surgical  
Advancements

Surgery and Science, Graduate School, Kyushu University Eiji Oki

## FACO/JSCO Joint Symposium 1

Thursday, October 24 14:20~15:50

Room 3 (201+202, 2F, Fukuoka International Congress Center)

### Next FACO Clinical Trial on Lung Cancer

Chair : Tetsuya Mitsudomi Izumi City General Hospital/Faculty of Medicine, Kindai University  
Nan Wu Department of Thoracic Surgery II, Peking University Cancer Hospital, China

**FACO-JS1-1** Status and prospects of treatment of metastatic lung  
cancer

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer  
Center, Korea Min Hee Hong

**FACO-JS1-2** Perioperative IO treatment of local advanced NSCLC

Department of Thoracic surgery II, Peking University Cancer Hospital, China  
Nan Wu

---

**FACO-JS1-3** Survey on Treatment Choices for Stage III Non-Small Cell Lung Cancer Among Thoracic Oncologists in Asia: A FACO Survey

Izumi City General Hospital/Faculty of Medicine, Kindai University  
Tetsuya Mitsudomi

**FACO/JSCO Joint Symposium 2**

Friday, October 25 14:30~16:00

Room 3 (201+202, 2F, Fukuoka International Congress Center)

**Remarkable Latest Clinical Trials on Digestive cancers in the World and Asia**

Chair : Sun Young Rha Yonsei University College of Medicine/ KCA Chairman-elect, Korea  
Jin Li Shanghai East Hospital, Tongji University/  
CSCO Deputy Chairperson of the Board of Supervisors/  
FACO Co-Chairman, China

**FACO-JS2-1** Latest Clinical Trials on Adjuvant and Neoadjuvant Treatment of LAGC in China

Peking University Cancer Hospital, China Xiaotian Zhang

**FACO-JS2-2** SCRUM-MONSTAR & CIRCULATE-Japan platform to accelerate precision oncology innovations; achievement and perspective

Division for the Promotion of Drug and Diagnostic Development, Department of  
Gastrointestinal Oncology, National Cancer Center Hospital East  
Takayuki Yoshino

**FACO-JS2-3** Updates of systemic chemotherapy & immunotherapy for bile duct cancers

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center,  
Sungkyunkwan University School of Medicine, Korea Joon Oh Park

**FACO-JS2-4** The hurdles of conducting the international investigator-initiated oncology clinical trials in Asia

Research & Development, Yuhan Corporation, Korea Yeul Hong Kim

**ASCO/JSCO Fellow Reports**

Thursday, October 24 9:00~9:45

Room 3 (201+202, 2F, Fukuoka International Congress Center)

Chair : Charles J. Dunton Gynecologic Oncology, OB/GYN, Mainline Healthcare, USA

**AJFP-1** My experience in ASCO/JSCO fellowship program 2024

Department of Coloproctological Surgery, Juntendo University Takahiro Irie

**AJFP-2** ASCO 2024 and observing outpatient clinics and surgeries at Georgetown University's Department of Oncology

Department of Gastroenterological Surgery, Graduate School of Medicine,  
Osaka Metropolitan University Hiroaki Kasashima

---

**AJFP-3** Current Status and Challenges of Drug Development in Japan and the U.S.: Insights from the ASCO/JSCO Fellowship 2024

Department of Medical Oncology, National Cancer Center Hospital  
Tomomi Sanomachi

**AJFP-4** ASCO/JSCO Fellowship Program 2024 Participation Report

Department of Obstetrics and Gynecology, Saitama Medical Center  
Kosuke Shigematsu

## ESMO/JSCO Fellow Reports

Thursday, October 24 9:45~10:30

Room 3 (201+202, 2F, Fukuoka International Congress Center)

Chair : Anna Patrikidou Gustave Roussy, France

**EJFP-1** Experiences and Insights from ESMO/JSCO Fellowship at Vall d'Hebron Institute of Oncology and ESMO Congress 2023

Department of Real-World Data R&D, Graduate School of Medicine,  
Kyoto University/Department of Clinical Oncology, Hospital, Kyoto University  
Tomohiro Kondo

**EJFP-2** ESMO/JSCO Fellowship program at Gustave Roussy in France

Department of Breast Medical Oncology, The Cancer Institute Hospital/Department  
of Advanced Medical Development, The Cancer Institute Hospital  
Yukinori Ozaki

**EJFP-3** Constructing a Novel Research Framework for Colorectal Cancer Care from Fukushima through University of Leeds and ESMO 2024

Department of Minimally Invasive Surgical and Medical Oncology, Fukushima  
Medical University/Department of Surgery, Southern Tohoku Research  
Institute for Neuroscience Hidetaka Kawamura

**EJFP-4** Training report of ESMO/JSCO fellowship program 2024: Training at the Gustave Roussy

Division of Urology, Kobe University Hospital Kotaro Suzuki

## JSCO2024 "Frontier" 1

Thursday, October 24 16:00~17:30

Room 3 (201+202, 2F, Fukuoka International Congress Center)

### Gastric Cancer, Hepatocellular Carcinoma, Head & Neck Cancer, Developmental therapeutics

Chair : Ken Kato Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital

Tomohiro Enokida Department of Head and Neck Medical Oncology, National Cancer Center Hospital East

Masafumi Ikeda Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East

**FR1-1** An Observational Study of Effectiveness and Safety of Nivolumab plus Chemotherapy for Untreated Advanced or Recurrent Gastric Cancer in Japanese Real-World Settings: 2nd interim analysis of G-KNIGHT

Kurashiki Central Hospital Shinichi Nishina

**FR1-2** Nivolumab (N) plus ipilimumab (I) vs lenvatinib (L) or sorafenib (S) as first-line (1L) treatment for Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW

Faculty of Medicine Hospital, Kindai University Masatoshi Kudo

**FR1-3** Superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for maxillary sinus cancer (JCOG1212): Final results of the T4a cohort

Department of Radiation Oncology, Aichi Cancer Center Hiroyuki Tachibana

**FR1-4** Multi-institutional registry study of the results of the Oncomine Dx Target Test for advanced thyroid cancer in Japan

Thyroid Cancer Multidisciplinary Treatment Committee, ATC Research Consortium of Japan, Japan Association of Endocrine Surgery Ken-Ichi Ito

**FR1-5** Phase I study of divarasib (GDC-6036) in Japanese patients (pts) with locally advanced or metastatic solid tumors with KRAS G12C mutations

Experimental Therapeutics, National Cancer Center Hospital East  
Yasutoshi Kuboki

---

**FR1-6** A Phase 1 Study of PARP inhibitor (Niraparib) plus HSP90 Inhibitor (Pimipitepsib) in Solid Tumors: Dose-escalation Results from the NiraPim (EPOC2102) Study

Department of General Internal Medicine, National Cancer Center Hospital East/  
Department of Experimental therapeutics, National Cancer Center Hospital East/  
Department of Medical Oncology, National Cancer Center Hospital East

Hiromichi Nakajima

**Discussant :**

**Sun Young Rha** Yonsei University College of Medicine/ KCA Chairman-elect, Korea

**Joon Oh Park** Division of Hematology-Oncology,  
Department of Medicine, Samsung Medical Center,  
Sungkyunkwan University School of Medicine, Korea

**Naoki Fukuda** Department of Medical Oncology, Cancer Institute Hospital  
of Japanese Foundation for Cancer Research

**Toshio Shimizu** Department of Pulmonary Medicine and Medical Oncology,  
Wakayama Medical University Hospital

---

**JSCO2024 "Frontier" 2**

Friday, October 25 8:20~9:50

Room 3 (201+202, 2F, Fukuoka International Congress Center)

---

**Gynecologic Cancer, Genitourinary Cancer, Lung Cancer**

**Chair : Koji Matsumoto** Department of Medical Oncology, Hyogo Cancer Center

**Takashige Abe** Department of Renal and Genitourinary Surgery,  
Graduate School of Medicine, Hokkaido University

**Hirotsugu Kenmotsu** Division of Thoracic Oncology, Shizuoka Cancer Center

**FR2-1** Tisotumab Vedotin vs Chemotherapy in Japanese Patients With Recurrent/Metastatic Cervical Cancer From the Phase 3 innovaTV 301 Study

Kurume University School of Medicine Shin Nishio

**FR2-2** Sub-group analysis by safety information associated with nivolumab treatment in patients with platinum-resistant (advanced or recurrent) ovarian cancer: NINJA trial

Osaka University Hospital Kenjiro Sawada

**FR2-3** Biomarker analysis for nivolumab treatment in patients with platinum-resistant (advanced or recurrent) ovarian cancer: NINJA trial

Kurume University Hospital Shin Nishio

**FR2-4** GDPP is a novel tumor-agnostic biomarker in blood for the diagnosis of bone metastasis

Department of Urology, Graduate School of Medicine, Osaka University  
Taigo Kato

**FR2-5** Patient preferences of treatment for the patients suffering from muscle-invasive urothelial carcinoma of bladder following radical cystectomy in Japan (SNUGGLE)

Sapporo Medical University Hospital Tetsuya Shindo

**FR2-6** IMpower010: Final DFS results from adjuvant atezolizumab in Japanese patients with resected NSCLC

Kanagawa Cancer Center Haruhiro Saito

Discussant :

Tadaaki Nishikawa Department of Obstetrics and Gynaecology,  
The Jikei University School of Medicine

Soichiro Yoshida Institute of Science Tokyo, Department of Urology

Patrick Forde Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

### JSCO2024 "Frontier" 3

Friday, October 25 10:00~11:30

Room 3 (201+202, 2F, Fukuoka International Congress Center)

#### Genitourinary Cancer

Chair : Masaki Shiota Department of Urology, Graduate School of Medical Sciences, Kyushu University

Nobuaki Matsubara Department of Medical Oncology, National Cancer Center Hospital East

**FR3-1** Updated Efficacy and Safety Results for Adjuvant Pembrolizumab (pembro) Versus Placebo (pbo) for Clear Cell Renal Cell Carcinoma (ccRCC) in the Phase 3 KEYNOTE-564 East Asian Subgroup

Faculty of Medicine, Department of Urology, University of Toyama

Hiroshi Kitamura

**FR3-2** Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC) in the East Asian subgroup from the randomized, open-label phase 3 LITESPARK-005 trial

Toranomon Hospital Yuji Miura

**FR3-3** Efficacy, Tolerability and Safety of [177Lu] Lu-PSMA-617 (177Lu-PSMA-617) in Patients with Progressive PSMA+mCRPC: A Prospective, Phase 2, Open-label, Single-arm Trial in Japan

Department of Renal and Genitourinary Surgery, Hokkaido University Hospital

Ryuji Matsumoto

**FR3-4** Real-world outcomes with avelumab + axitinib (A+Ax) by IMDC risk classification in patients (pts) with advanced renal cell carcinoma (aRCC): subgroup analysis from the long-term J-DART2 study in Japan

Department of Urology, School of Medicine, Keio University Mototsugu Oya

**FR3-5** Final analysis of postmarketing surveillance (PMS) for the safety and effectiveness of avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan

Department of Urology, St. Marianna University School of Medicine Eiji Kikuchi

**FR3-6** ANNAR biomarker study: Fibroblast growth factor receptor alterations (FGFRalt) in locally advanced or metastatic urothelial cancer (mUC) and non-muscle invasive bladder cancer (NMIBC)

Department of Medical Oncology, National Cancer Center Hospital East  
Nobuaki Matsubara

Discussant :

Kazuhiro Matsumoto Department of Urology, Keio University School of Medicine

Takashi Kobayashi Department of Urology, Kyoto University Graduate School of Medicine

## JSCO2024 "Frontier" 4

Saturday, October 26 8:30~10:00

Room 3 (201+202, 2F, Fukuoka International Congress Center)

### Gastrointestinal Cancer

Chair : Eiji Oki Department Surgery and Science, Graduate School of Medical Sciences, Kyushu University

Akihito Kawazoe Department of Gastrointestinal Oncology, National Cancer Center Hospital East

**FR4-1** Combined Analysis of ENSEMBLE-1 and ENSEMBLE-2 Phase II studies Evaluating TNT in Local Advanced Rectal Cancer in Japan

Department of Gastroenterological Surgery, Osaka International Cancer Institute  
Yoshinori Kagawa

**FR4-2** Clinical and Genomic Characteristics of Colorectal Cancer in Adolescents and Young Adults: An Ancillary Analysis of the GALAXY Study

Department of General Surgery, Kurashiki Central Hospital Ayako Ueno

**FR4-3** First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC): updated results from PROCEADE-CRC-01

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital  
Ken Kato

**FR4-4** Final results of the JACCRO CC-16: ramucirumab plus FOLFIRI for RAS wild-type anti-EGFR antibody refractory metastatic colorectal cancer

Department of Gastroenterological Surgery, Sendai Open Hospital  
Naoya Akazawa



**FR4-5** Sequential treatment with regorafenib and trifluridine/tipiracil ± bevacizumab for metastatic colorectal cancer

Department of Medical Oncology, Teine Keijinkai Hospital Atsushi Ishiguro

**FR4-6** An Observational Study of BRAF Inhibitor Combination Therapy for *BRAF*-mutated Metastatic Colorectal Cancer Patients: Real-World Evidence from BEETS Trial (JACCRO CC-18)

Department of Medical Oncology, Faculty of Medicine, Kindai University  
Chiaki Inagaki

Discussant :

**Benjamin A. Weinberg** Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, USA

**Akihito Kawazoe** Department of Gastrointestinal Oncology, National Cancer Center Hospital East

**Atsuo Takashima** National Cancer Center Hospital, Department of Gastrointestinal Medical Oncology

**Hiroki Osumi** Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research

## International Oral 1

Thursday, October 24 9:00~9:50

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Biomarkers

Chair : **Mikihiro Fujiya** Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University

**IO1-1** TRIM27, identified by TEP RNA-sequencing, emerged as a potential biomarker for malignant ground-glass opacities diagnosis, mediating glycolysis of non-small cell lung cancer cells partially via HOXM1

Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, China Yan Hu

**IO1-2** Analytical validation of NeXT Personal<sup>®</sup>, an ultra-sensitive personalized circulating tumor DNA assay

Personalis, Inc., USA Kedar Hastak

**IO1-3** Comprehensive Pan-cancer Analysis of HSPG2 as a Marker for Prognosis

Department of Thoracic Surgery, Peking University Third Hospital, China  
Huayu He

**IO1-4** Molecular classification of esophageal squamous cell carcinoma based on immunogenic cell death related damage-associated molecular pattern gene signature

Department of Oncology Radiationtherapy, Nanjing Medical University Affiliated Changzhou Second People's Hospital, China Jianlin Wang

**IO1-5 Multi-Sequence MRI Based Radiomics Nomogram for Prediction Expression of Programmed Death Ligand 1 in Thyroid Epithelial Tumor**

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University,  
China Jing He

**IO1-6 Withdrawn**

**International Oral 2**

Thursday, October 24 10:00~10:50

Room 14 (504+505, 5F, Fukuoka International Congress Center)

**Bone and Soft Tissue / Hematopoietic Organs**

Chair : Hisakazu Nishimori Department of Hematology, Hiroshima City Hiroshima Citizens Hospital

**IO2-1 Blockade of TIGAR Prevents CD8+ T Cell Dysfunction and Elicits Anti-AML Immunity**

Department of Hematology, The First Affiliated Hospital of Nanjing Medical  
University, Jiangsu Province Hospital, China Sun Qian

**IO2-2 Simvastatin Modulates DLBCL Cell Fate: In Vitro and In Vivo Insights**

Department of Hematology, Taizhou Central Hospital (Taizhou University Hospital),  
China Wenwen W. Wang

**IO2-3 High-dimensional immune profiling identifies APOE-mediated macrophage immunosuppression in ALK+ inflammatory myofibroblastic tumor**

Surgery for Retroperitoneum and Soft Tissue Tumors, Department of General Sur-  
gery, Zhongshan Hospital, Fudan University, China Jiongyuan Wang

**IO2-4 Multimodal integration of radiology, pathology and transcriptomics for prediction of response to neoadjuvant therapy in patients with retroperitoneal liposarcoma: a retrospective multicohort analysis**

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong  
University, China Lijie Ma

**IO2-5 Quality of surgery and outcome for giant retroperitoneal liposarcoma treated within semi-abdominal En Bloc resection using vascular priority central approach: a retrospective cohort**

Department of General Surgery, Zhongshan Hospital (Xuhui Branch), Fudan  
University, China Pei Dang Fan

**IO2-6 Clinicopathological and molecular genetic characteristics of diffuse large B-cell lymphoma with Concomitant MYC/BCL6 gene rearrangements**

Department of Pathology, Fudan University Shanghai Cancer Center, China/  
Department of Oncology, Fudan University Shanghai Medical College, China  
Bao-Hua Yu

## International Oral 3

Thursday, October 24 11:00~11:50

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Urology

Chair : Mikio Sugimoto Department of Urology, Faculty of Medicine, Kagawa University

**IO3-1** A novel six-zone method to guide delineation of clinical target volume (CTV) for postoperative radiotherapy of prostate cancer, based on the distribution of prostate bed recurrence by PSMA PET

Department of Radiation Oncology, Peking University First Hospital, China

Huan Zhang

**IO3-2** Noninvasive detection and recurrence monitoring for non-muscle-invasive bladder cancer via urine tumor DNA: a prospective study

Department of Urology, Fudan University Shanghai Cancer Center, China/

Department of Oncology, Shanghai Medical College, Fudan University, China

Junlong Wu

**IO3-3** Dissecting the Genomic Landscape, Immunogenic Features, and Clinical Outcomes of Muscle-Invasive Urothelial Carcinoma with PIK3CA Alteration

Department of Urology, Fudan University Shanghai Cancer Center, China

Yuan Chang

**IO3-4** Deep learning-based multimodel prediction for disease-free survival status of patients with clear cell renal cell carcinoma: a multicenter cohort study

Urology, Renji Hospital Shanghai Jiao Tong University School of Medicine, China

Chen Siteng

**IO3-5** TIGIT and PD-1 expression atlas predicts survival and therapeutic responses in muscle-invasive bladder cancer

Urology, Fudan University Shanghai Cancer Center, China Yu Zhu

**IO3-6** A panel of dysregulated circulating microRNA as a diagnostic biomarker for Prostate Cancer Progression

Department of Biochemistry, King George's Medical University, India

Anveshika Manoj

## International Oral 4

Thursday, October 24 14:20~15:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Lung 1

Chair : Tomoyoshi Takenaka Department of Thoracic Surgery, Kyushu University Hospital

**IO4-1** Inter-domestication between oligodendrocytes and tumor cells to promote lung cancer brain metastasis by secreting ERBB3 protein

Department of Neurosurgery, Fudan University Shanghai Cancer Center, Fudan University, China Liangdong Li

**IO4-2** An atlas of N6-methyladenine (6mA) DNA modification in squamous cell lung carcinomas by long read sequencing

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, China Xiaoshun Shi

**IO4-3** A Multicenter Retrospective Analysis of Immunotherapy Utilization in Pleural Mesothelioma: Insights into Real-World and Immunological Landscape

Department of Radiation Oncology, Shanghai Pulmonary Hospital, China Xiaoling Xu

**IO4-4** SLC40A1+macrophages contribute to EGFR-TKI resistance by remodeling immunosuppressive tumor microenvironment in EGFR-mutated lung cancer

Shanghai Pulmonary Hospital, Oncology, Tongji University, School of Medicine, China Fengying Wu

**IO4-5** The crosstalk between neutrophil and lymphocyte to predict the response to chemoimmunotherapy in non-small cell lung cancer patients

Thoracic Department I, Thoracic Department, Hunan Cancer Hospital, China Lemeng Zhang

**IO4-6** AXL as a Preclinical Acquired Resistance Mechanism Against MET-TKI Treatment in MET activated Non-Small Cell Lung Cancer

Guangdong People's Hospital, China Anna Li

## International Oral 5

Thursday, October 24 15:20~16:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Lung 2

Chair : Masayuki Takeda Department of Cancer Genomics and Medical Oncology, Nara Medical University

**IO5-1** Efficacy of BRAF-targeted therapy and Chemo-Immunotherapy in metastatic BRAF-Mutated Lung Cancer: A Single-Center Retrospective data

Ward 2, Medical Oncology, The First Affiliated Hospital of Zhengzhou University, China Ning N. Yan

**IO5-2** Different Treatment Modalities on the Prognosis of Patients with Stage I-IIIa Small Cell Lung Cancer: A Population Based Study

Thoracic Surgery, Peking University Third Hospital, China Chutong Lin

**IO5-3** Phase II Clinical Study of Envafolimab Combined with Endostatin and Chemotherapy as a First-Line Treatment for Driver Gene-Negative Advanced Non-Small Cell Lung Cancer

Radiotherapy Department, Shandong First Medical University Affiliated Cancer Hospital, China Chuanwang Miao

**IO5-4** Assessing the Efficacy of Segmentectomy versus Lobectomy: A Propensity Score Matched Analysis of Perioperative Outcomes in Non-Small Cell Lung Cancer Treatment

Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institution, China Wei Xing

**IO5-5** Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in resectable non-small cell lung cancer

Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, China Siying Ren

**IO5-6** Efficacy and safety of perioperative immunotherapy for non-small cell lung cancer: a network meta-analysis

Department of Oncology, the Second Xiangya Hospital, Central South University, China/Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, China/Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, China/Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, China Fang Wu

## International Oral 6

Thursday, October 24 16:20~17:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Lung 3

Chair : Tatsuya Yoshida Department of Thoracic Oncology/Experimental Therapeutics, National Cancer Center Hospital

**IO6-1** Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated non-small-cell lung cancer: a PSM-IPTW cohort study

Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, China/Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Germany Jian-Guo Zhou

**IO6-2** Withdrawn

**IO6-3** DEB-BACE for the treatment of intermediate-stage non-small cell lung cancer in the elderly population: a propensity-matched study

Cancer Center, The Fifth Hospital Affiliated to Wenzhou Medical University, China Jianfei Tu

**IO6-4** Deep learning-based intraoperative prediction of visceral pleural invasion in lung cancer for surgical extent decisions

Thoracic, Peking University People's Hospital, China Jian Zhou

**IO6-5** Machine learning models based on XGBoost algorithm to predict prognosis of lung cancer brain metastases

Thoracic Surgery, Peking University Third Hospital, China Chutong Lin

**IO6-6** Improved prognostication of overall survival after radiotherapy in lung cancer patients by an interpretable machine learning model integrating lung and tumor radiomics and clinical parameters

Department of Radiation Oncology, Zhejiang Cancer Hospital, China/Department of Radiation Oncology (Maastr), Maastricht University Medical Centre+, Netherlands Zhen Zhang

## International Oral 7

Friday, October 25 8:20~9:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Upper GI

Chair : Yuji Miyamoto Department of Gastroenterological Surgery, Kumamoto University

**IO7-1** Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study

Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, China Jun Peng

**IO7-2** Short Term Survival for Locally Advanced Esophageal Squamous cell Carcinoma is Superior After Neoadjuvant Chemoimmunotherapy Compared with Chemoradiotherapy

Esophageal Surgery, Thoracic Surgery, Tianjin Medical University Cancer Hospital, China Xiaofeng Duan

**IO7-3** Safety and Feasibility of Personalized Neoantigen DC Vaccines in Postoperative Esophagus Squamous Cell Carcinoma: A Phase 1b Trial

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China Yueyun Chen

**IO7-4** Application of a new retraction method in laparoscopic gastrectomy for gastric cancer

Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University, China Zhang Shun

**IO7-5** Efficacy and toxicity of modified DCF (mDCF) as first-line chemotherapy in patients with advanced and recurrent gastric cancer

Department of Medical Oncology, Medical Oncologist in Department of Medical Oncology, Vietnam National Cancer Hospital, Sub-I and PI at Cancer Research and Clinical Trial Center, Vietnam/Cancer Research and Clinical Trials Center, Vietnam Anh T. Dinh

**IO7-6** Prognostic impact of lymph node status after D2 resection with chemo-radiation for locally advanced gastric cancer: Results from a prospective randomized control study

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), China/Department of Radiobiology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, China Ning Li

## International Oral 8

Friday, October 25 9:20~10:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Colorectal

Chair : Kazuhiro Sakamoto Department of Coloproctological Surgery, Juntendo University Faculty of Medicine

**IO8-1** (P) RR inhibition attenuates the progression of colorectal cancer with KRAS mutation by inducing KRAS degradation and regulating the KRAS-HSL-lipid metabolism axis

Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, China Juan Wang

**IO8-2** Impact and Predictive Value of Intermuscular Fat and Skeletal Muscle Radiodensity on Prognosis in Colorectal Cancer Patients: a population-based cohort study

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Union Hospital, Huazhong University of Science and Technology, China/Hubei Key Laboratory of Biological Targeted Therapy, China Cao Yinghao

**IO8-3** Circulating Tumor DNA Guided Therapeutic Strategies for mCRC Patients with Multiple Small Pulmonary-limited Nodules - Updated results from the Open-Label, Prospective, Phase II Cohort Study

Department of Medical Oncology, Fudan University Shanghai Cancer Center, China Jinjia Chang

**IO8-4** An artificial intelligence system integrating deep learning-proteomics, pathomics and clinicopathological features to determine risk of T1 colorectal cancer metastasis to lymph node

Colorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, China Yijiao Chen

**IO8-5** Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): A phase Ib/II, open-label, randomized study

Department of Medical Oncology, Fudan University Shanghai Cancer Center, China Wenhua Li

**IO8-6** The nicotinamide phosphoribosyl transferase antagonist FK866 induces ferroptosis and orchestrates the immune microenvironment through NAD/STAT3/GPX4 signaling axis in colorectal cancer

Medical Oncology, Second Affiliated Hospital, Zhejiang University, China Chenyang Ye



## International Oral 9

Friday, October 25 10:20~11:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### HBP

Chair : Koji Miyanishi Department of Medical Oncology, Sapporo Medical University School of Medicine

**IO9-1 Simultaneous Resection versus Staged Resection for Conversion Surgery for Initially Unresectable Colorectal Liver Metastasis: A Prospective Cohort Study**

Colorectal Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, China Yijiao Chen

**IO9-2 Hypoxia related SPP1+ macrophages may lead to poor response to combination immunotherapy in patients with MSS metastatic colorectal cancer liver metastases**

Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, China/Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, China Ning Zhu

**IO9-3 Effect of the expression of ARFGAP1 on the behavior of Hepatocellular carcinoma**

Department of Gastroenterology, Chongqing University Cancer Hospital, China/Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, China Ji Wen

**IO9-4 Relationship between Post-Ablation Fever and Prognosis in Initial Hepatocellular Carcinoma: A 15-Year Multi-center, Retrospective Cohort Study**

Department of Interventional Ultrasound, 5th Medical Center of Chinese PLA General Hospital, China Qian Cai

**IO9-5 HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment**

Pathology, Nanjing Drum Tower Hospital, China Pu Xiaohong

**IO9-6 Survival comparison of neoadjuvant chemotherapy followed by irreversible electroporation versus conventional resection for locally advanced pancreatic cancer**

Department of Pancreatobiliary Surgery, Sun Yat-sen University Cancer Center, China Chaobin He

## International Oral 10

Saturday, October 26 8:30~9:20

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Neurology / Head and Neck

Chair : Daisuke Sano Department of Head and Neck Surgery, Yokohama City University

- IO10-1** Role of PSMA PET based Radiotherapy planning for Reirradiation in Inoperable High Grade Glioma (HGG) patients- Single Centre Prospective Observational study  
Radiotherapy & Oncology, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), India Umesh Velu
- IO10-2** Survival Assessment of IDH wild Type High Grade Glioma (HGG) patients treated from Tertiary Care cancer center- A single institutional Retrospective Observational study  
Radiotherapy & Oncology, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), India Umesh Velu
- IO10-3** Safety and efficacy of cyberknife radiosurgery plus anlotinib hydrochloride in patients with recurrent glioblastoma: a prospective phase II single-arm study (HSCK-002)  
Radiosurgery Division, Neurosurgery Department, Huashan Hospital Fudan University, China Yun Guan
- IO10-4** Deep Learning-based Fully Automated Detection and Segmentation of Lymph Nodes on Computed Tomography for Head and Neck Cancer: A Multi-center Study  
Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, China Wenjun Liao
- IO10-5** HMGB3 recruits SSBP1 to induce its nuclear translocation and remodels mitochondrial metabolism to promote lung cancer brain metastasis  
Department of Neurosurgery, Fudan University Shanghai Cancer Center, Fudan University, China Liangdong Li
- IO10-6** Assessing the Utility of Red Blood Cell Distribution Width-Albumin Ratio (RAR) as a Predictive Tool in Nasopharyngeal Carcinoma Prognosis  
Department of Oncology, the Second Xiangya Hospital of Central South University, China Tao Hou

## International Oral 11

Saturday, October 26 9:25~10:15

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Uterus / Ovary

Chair : Tsuyoshi Saito Department of Obstetrics & Gynecology, Sapporo Medical University

**IO11-1 Prediction of Recurrence Sites in Endometrial Cancer Using Various Machine Learning Techniques**

Obstetrics & Gynecology, Chungnam National University, Korea Wonkyo Shin

**IO11-2 A systematic review of the surgical management of Intra-venous Leiomyomatosis**

Graduate School of Medicine, University of Wollongong, Australia/  
Department of Gynaecological Surgery, St Vincent's Hospital Sydney,  
Australia Wei H. Lim

**IO11-3 Stage, treatment and survival of low-grade serous ovarian carcinoma in the United States**

Department of Gynecologic Oncology, National Cancer Center/National Clinical  
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences  
and Peking Union Medical College, China Zhe Li

**IO11-4 Patient-reported symptom burden and circulating cytokines undergoing chemotherapy: A pilot study in patients with ovarian cancer**

Obstetrics and Gynecology, Obstetrics and Gynecology of the Affiliated Nanchong  
Central Hospital of North Sichuan Medical College, The Affiliated Nanchong Central  
Hospital of North Sichuan Medical College, China/State Key Laboratory of  
Ultrasound in Medicine and Engineering, State Key Laboratory of Ultrasound in  
Medicine and Engineering, Chongqing Medical University, China Ying Tang

**IO11-5 Comparison of Rapid Recovery Outcomes between vNOTES Hysterectomy and Laparoscopic Hysterectomy**

Gynecology, Obstetrics and Gynecology of The Affiliated Nanchong Central Hospital  
of North  
Sichuan Medical College, China Ying Tang

**IO11-6 Treatment patterns and prognosis of patients with clear cell carcinoma of the cervix: a population-based cohort study**

The Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital of Sun  
Yat-Sen University, China Jing Li

## International Oral 12

Saturday, October 26 10:20~11:10

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Breast 1

Chair : Takaaki Fujii Division of Breast and Endocrine Surgery, Gunma University

**IO12-1** Spatiotemporal trends of breast cancer and attributable risk factors in adolescents and young adults between 1990 and 2019

Department of Breast Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou Hospital of Traditional Chinese Medicine, China Tian Lan

**IO12-2** Regional nodal irradiation fields in breast cancer with 1-2 positive sentinel lymph nodes without axilla dissection

Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao

**IO12-3** Clinical study of HR+/HER2- breast cancer (neo) adjuvant endocrine therapy strategy optimization

Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao

**IO12-4** Internal mammary nodal irradiation guided by internal mammary sentinel lymph node biopsy after neoadjuvant therapy in breast cancer

Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao

**IO12-5** Optimal management of breast cancer patients with clinically node-negative/ imaging node-abnormal disease

Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao

**IO12-6** The optimal timing of breast cancer surgery after COVID-19 infection: An observational study

Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao

## International Oral 13

Saturday, October 26 11:15~12:05

Room 14 (504+505, 5F, Fukuoka International Congress Center)

### Breast 2

Chair : Koichiro Tsugawa Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine

**IO13-1** Withdrawn

**IO13-2** Single-cell transcriptome sequencing of neoadjuvant endocrine therapy

Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao

- IO13-3** Integrating ctDNA to predict response after neoadjuvant chemotherapy combined with immune therapy in HER2-low triple-negative breast cancer  
Breast Cancer Center, Shandong Cancer Hospital, China Bi Zhao
- IO13-4** ZNF689 promotes homologous recombination via NBS1 ubiquitination and its loss confers sensitivity to PARP inhibitors in triple-negative breast cancer  
Department of Breast Surgery, Fudan University Shanghai Cancer Center, China  
Ge Li-Ping
- IO13-5** A novel chimeric antigen receptor dendritic cell in treating breast cancer in mice  
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, USA Zhenqiang Yao
- IO13-6** Establishment of risk score prognostic model of breast cancer (BRCA) through exploring the NGEF-related molecular features  
Department of Oncology Medicine, Fujian Medical University Union Hospital, China  
Qian Xu

## International Poster 1

Thursday, October 24 17:00~17:35

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Lung (Drug 1)

Chair : Tatsuro Okamoto Department of Thoracic Surgery, Beppu Medical Center

- IP1-1** The efficacy and safety of nab-paclitaxel plus anlotinib in small-cell-Lung-Cancer for third-line therapy  
Oncology, Department of Oncology, Binzhou Medical University Hospital, China  
Li-Jun Tian
- IP1-2** M1 macrophage-derived exosomes enhance the sensitivity of non-small cell lung cancer to cisplatin through reprogramming macrophages from M2 to M1 and modulating HIPPO signaling pathway  
Thoracic Surgery, The First Hospital of China Medical University, China  
Xin Zhang
- IP1-3** EML4-ALK Positive Lung Adenocarcinoma with stage IIIB (N3) gets pathological complete remission: Case report and literature review  
Thoracic Surgery, Surgery, PUMCH, China Zhongxing Bing

**IP1-4** Predicting the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKI alone using nomograms based on CT radiomic and clinicopathologic factors

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, China Junfeng Zhao

**IP1-5** Remarkable response of a novel NISCH-ALK fusion to perioperative lorlatinib in a stage IIIB lung adenocarcinoma

Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, China Yan Hu

## International Poster 2

Thursday, October 24 17:00~17:35

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Lung (Drug 2)

Chair : Shingo Matsumoto Department of Thoracic Oncology, National Cancer Center Hospital East

**IP2-1** Adjuvant treatment options after neoadjuvant chemotherapy combined with immunotherapy and surgery in patients with non-small cell lung cancer

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China Junfeng Zhao

**IP2-2** Nomogram-based Prediction of Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients

Department of Radiation Oncology, Chongqing University Cancer Hospital, China Dan Tao

**IP2-3** Serum prognostic indexes in older patients with non-small cell lung cancer receiving immunotherapy

Department of Oncology, The Second Xiangya Hospital of Central South University, China Dan Fan

**IP2-4** Immunotherapy combined with antiangiogenic therapy as third- or further-line therapy for stage IV non-small cell lung cancer patients with ECOG performance status 2: A retrospective study

Oncology, Department of Oncology, Binzhou Medical University Hospital, China Li-Jun Tian

**IP2-5** Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: a real-world study

Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China Ying Li

## International Poster 3

Thursday, October 24 17:00~17:50

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Lung (Radiation)

Chair : Yoshiyuki Shioyama Ion Beam Therapy Center, SAGA HIMAT Foundation

**IP3-1** SWItch/Sucrose NonFermentable Complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, China

Yu Gu

**IP3-2** Thoracic radiotherapy for extensive stage small cell lung cancer after first line immunotherapy and chemotherapy: A phase II Clinical Trial

Radiation Oncology, Zhejiang Cancer Hospital, China Fang Min

**IP3-3** Clinical observation of radiotherapy target delineation of primary upper lobe lung cancer with negative supraclavicular lymph nodes in localized small cell lung cancer

Department of Radiotherapy, The Affiliated Hospital of Qingdao University, China/

Qingdao University, China Yonglong Jin

**IP3-4** The effect of radiation X-ray on myocardial cell injury and Neuregulin-1/ErbB signaling pathway in rats

Medical Oncology, Affiliated Hospital of Yanan University, China Liu Yiting

**IP3-5** Sequential immunomaintenance therapy after concurrent radiochemotherapy and cervical prophylactic irradiation is expected to improve the clinical benefits of limited stage small cell lung cancer

Department of Radiotherapy, The Affiliated Hospital of Qingdao University, China/

Qingdao University, China Yonglong Jin

**IP3-6** Efficacy and safety evaluation of first-line immunotherapy combining with chemotherapy followed by consolidated thoracic radiotherapy for stage IV NSCLC

Oncology, Binzhou Medical University Hospital, China Li-Jun Tian

**IP3-7** Efficacy and Safety Aiming at the Combined-Modality Therapy of External Beam Radiotherapy (40Gy) and Iodine-125 Seed Implantation for Locally Advanced NSCLC in the Elderly

Oncology, Department of Oncology, Binzhou Medical University Hospital, China

Li-Jun Tian

## International Poster 4

Thursday, October 24 17:00~18:00

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Lung (Clinical)

Chair : Toshiyuki Kozuki National Hospital Organization Shikoku Cancer Center

**IP4-1** Predicting prognosis in patients with stage IA lung adenocarcinoma with a micropapillary component using a nomogram based on computed tomography radiomics and clinicopathologic factors

Department of Respiratory Oncology, Shandong Cancer Hospital and Institute,  
Shandong First Medical University and Shandong Academy of Medical Sciences,  
China Ying Li

**IP4-2** A Case Report of Myelosuppression after Pamiparib combined with Temozolomide Treatment for Small Cell Lung Cancer

Medical Oncology, Cancer Center, Inner Mongolia People's Hospital, China  
Zhihui Cai

**IP4-3** Significance of upper paratracheal lymph node resection in stage IB right lung cancer

Minimally Invasive Surgery Center, Thoracic Surgery, Beijing Chest Hospital, Capital  
Medical University, China Feng Wang

**IP4-4** The network pharmacology and Mechanism verification of Wall-removed Ganoderma Lucidum Spore Powder combined with anti-PD-L1 antibody in Lung Cancer and the Effects on the Functions of T Lymphocytes

Department of Pharmacy, Zhejiang Cancer Hospital, China Zhang Hongyan

**IP4-5** Lactobacillus metabolites relieves the adverse reaction rash and diarrhea induced by EGFR TKI: two case reports and literature review

Department of Clinical Nutrition, Chongqing University Cancer Hospital, China  
Mengting Chen

**IP4-6** Knowledge, attitudes, and Current practices toward lung cancer palliative care management in China: a national survey

Department of Clinical Nutrition, Chongqing University Cancer Hospital, China  
Mengting Chen

**IP4-7** Lactobacillus metabolites relieves the reactive cutaneous capillary endothelial proliferation (RCCEP) induced by Checkpoint inhibitors: a case report and review of literature

Department of Clinical Nutrition, Chongqing University Cancer Hospital, China  
Mengting Chen



**IP4-8** Exploration of an innovative management model based on digital follow-up of lung cancer patients

Thoracic Cancer, Oncology, Beijing Cancer Hospital, China **Xue Yang**

## International Poster 5

Thursday, October 24 17:00~18:00

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Lung (TR / Clinical Trial)

Chair : Yukio Hosomi Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

**IP5-1** KRAS inhibitor AMG510 combined with radiotherapy activates lung cancer immunity in an animal model

Radiation Oncology, Department of Oncology, Jinan Central Hospital, China

**Yawen Zheng**

**IP5-2** Prognostic value of Inflammation-immunity-nutrition score in NSCLC patients

Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University,

China **Chengcheng Yang**

**IP5-3** The Study on the Role of LncRNA MANCR/miR-767-5p/Glycodelin in Lung Adenocarcinoma

Department of Oncology, Peking University People's Hospital, China

**Lingling Zhang**

**IP5-4** Clinical treatment selected by patient-derived organoid in a patient with stage IV lung adenocarcinoma with unique ALK alternation

Postgraduate Training Base Alliance, Wenzhou Medical University, China

**Huihui Li**

**IP5-5** Tislelizumab plus Standard Chemotherapy as First-line treatment in Unresectable or Recurrent Thymic epithelial tumors (TETs): A Prospective, Single-Arm Trial

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University,

China **Wen Gao**

**IP5-6** The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer

Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China **Min Tang**

**IP5-7** Single-arm, multi-center, prospective clinical study of recombinant human endostatin combined with afatinib and Ticeo in second-line treatment of advanced lung squamous cell carcinoma

Integrative Medicine Oncology, The First Affiliated Hospital of Anhui Medical University, China **Yang Chen**

**IP5-8** Study the efficacy of elemene liposomes for the treatment of cancer cachexy in non-small-cell lung cancer

Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China Yunchao Zhang

**International Poster 6**

Thursday, October 24 17:00~17:50

Poster Room (Arena, 1F, Marine Messe Fukuoka)

**Lung (Basic 1)**

Chair : Masafumi Kataoka Akaiwa Medical Association Hospital

**IP6-1** Effect and mechanism on apoptosis of human non-small cell lung cancer cells induced by p-Hydroxycinnamaldehyde from Cochinchina Momordica Seeds through NF- $\kappa$ B signaling pathway

Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, China Fan Zhang

**IP6-2** SIRT5 participates in the suppressive tumor immune microenvironment of EGFR-mutant lung adenocarcinoma by regulating the succinylation of ACAT1

Department 1 of Gynecologic Oncology, Jilin Cancer Hospital, China/ Postdoctoral Research Workstation, Jilin Cancer Hospital, China Sun Xiaodan

**IP6-3** Influence of RNA 5-cytosine methylation patterns on tumour microenvironment infiltration in lung squamous cell carcinoma

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, China Xiaoshun Shi

**IP6-4** Analyses of PRR11 sense-antisense pair on biological functions, tumor microenvironment, immunotherapy responses in lung adenocarcinoma

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, China Xiaoshun Shi

**IP6-5** Systematic impact of PD-1-based lncRNA immunophenotype on NSCLC prognosis and drug sensitivity

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, China Xiaoshun Shi

**IP6-6** FLT3LG improves therapeutic sensitivity to anti-PD-1 therapy by modulating immune cell infiltration in NSCLC

Department of Thoracic Surgery, The First Affiliated Hospital of Xian Jiaotong University, China Sida Qin

**IP6-7** Traditional Chinese medicine for clearing heat and detoxifying affects macrophage M1 polarization by regulating miR-196a-5p/MARCH7/c-Myc axis, reversing radiation resistance in lung cancer

Oncology, The First Affiliated Hospital of Guangxi University of Chinese Medicine,  
China Yao Fei

## International Poster 7

Thursday, October 24 17:00~17:50

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Lung (Basic 2)

Chair : Kentaro Tanaka Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University

**IP7-1** KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axis

Department of Pathology, Kunming Medical University, China Li Leilei

**IP7-2** Clinicopathological characterization and therapeutic exploration of pulmonary enteric adenocarcinoma

Department of Radiation Oncology, Weifang People's Hospital, China  
Geng Xiaotao

**IP7-3** Systematic Analysis and Identification of Molecular Subtypes of Propionate Metabolism-Related Genes and Prognosis Prediction in Lung Adenocarcinoma

Thoracic Surgery Department, The Fourth Hospital of Hebei Medical University,  
China Zhifeng Li

**IP7-4** Predictors for acute exacerbation of interstitial pneumonia following lung cancer surgery: a multicenter study

Thoracic Surgery, Peking University Third Hospital, China Chutong Lin

**IP7-5** Plasma PD-L1 Concentration: Implications for Chronic Pain Management in Post-VATS Lung Cancer Patients

Anesthesiology, Peking University People's Hospital, China Xue Tian

**IP7-6** THBS2: A Potential Therapeutic Target for NSCLC Patients with Diabetes

Department of Medical Oncology, Sichuan Cancer Hospital & Institute/  
University of Electronic Science and Technology of China, China Jing Ding

**IP7-7** Forkhead box N1 expression is increased in lung squamous cell carcinoma and it may serve as a potential diagnostic biomarker

Medical Oncology, Department of Oncology, Shaanxi Provincial Peoples Hospital,  
China Xi Wang

## International Poster 8

Thursday, October 24 17:00~17:35

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Urology

Chair : Nobuyuki Tanaka Department of Urology, Keio University School of Medicine

**IP8-1** RC48-ADC down-regulated the tumor PD-L1 expression and enhanced CD8+T cell infiltration improved the efficacy of immune checkpoints inhibitor therapy in bladder cancer

Tumor, Urology, Xiangya Hospital, Central South University, China  
Jiatong Xiao

**IP8-2** Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for high-risk non-muscle-invasive bladder cancer patients unresponsive to BCG

Surgery, Department of Urology, Sun Yat-Sen University Cancer Center, China  
Zhiyong Li

**IP8-3** Efficacy and safety of radium-223 dichloride for mCRPC: A real-world clinical practice from Fudan University Shanghai Cancer Center

Department of Urology, Fudan University Shanghai Cancer Center, China  
Hongkai Wang

**IP8-4** Postoperative metastatic targeted and immunotherapy for renal cancer

Urology, Surgery, Second Hospital of Dalian Medical University, China  
Wang Yanlong

**IP8-5** Primary Bilateral Macronodular Adrenal Hyperplasia

Urology, Surgery, Second Hospital of Dalian Medical University, China  
Wang Yanlong

## International Poster 9

Thursday, October 24 17:00~17:45

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Hematopoietic / Lymphatic

Chair : Yasushi Miyazaki Atomic Bomb Disease Institute, Nagasaki University

**IP9-1** Diffuse Large B-Cell Lymphoma with Concomitant Prostate Cancer

Urology, Surgery, Second Hospital of Dalian Medical University, China  
Wang Yanlong

**IP9-2** In Multiple Myeloma PRUNE1-IGF2BP3 forms a positive feedback loop by stabilizing SOX4 mRNA in an m6A-dependent manner and enhances the HIF-1 signaling pathway

Lymphoma, Hematology, The Affiliated Hospital of Qingdao University, China/  
Hematology, Fudan University Zhongshan Hospital, China Yawen Wang

**IP9-3** Identification and immunoassay of prognostic genes associated with the complement system in acute myeloid leukemia

Hematology, The First Affiliated Hospital of Chongqing Medical University, China  
Chen Liu

**IP9-4** Cervical Granulocytic Sarcoma without Acute Leukemia: A Case Report and Review of 42 Additional Cases

School of Medicine, Shaoxing University, China Wenting Zhu

**IP9-5** Carfilzomib-Induced Thrombotic Microangiopathy: A Case Report and Literature Review

Internal Medicine, Hangzhou Normal University Affiliated Hospital, China  
Tao A. Li

**IP9-6** Tislelizumab in combination with CPEL (Chidamide, Prednisone, Etoposide, Lenalidomide) followed autologous stem cell transplant (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Lymphoma, Hematology, The Affiliated Hospital of Qingdao University, China  
Yawen Wang

## International Poster 10

Thursday, October 24 17:00~17:50

Poster Room (Arena, 1F, Marine Messe Fukuoka)

## Clinical Related

Chair : Osamu Itano Department of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery, International University of Health and Welfare School of Medicine

**IP10-1** A phase II study of Fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma (STS)

Department of Medical Oncology, Fudan University Shanghai Cancer Center, China/  
Department of Oncology, Shanghai Medical College, Fudan University, China  
Xiaowei Zhang

**IP10-2** Sacituzumab in posterior line therapy of advanced malignant tumors

Department of Oncology, Nanjing Benq Medical Center, China Yang Wang

**IP10-3** Extra-gastrointestinal stromal tumors (EGISTs): A Case Report and Literature Review

Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine,  
Tongji University, China Zhang Shun

**IP10-4** Efficacy and safety of megestrol acetate plus zusanli (ST 36) point injection in the prevention of CINV

3, Medical Oncology, Huanggang Central Hospital, China Shengwei Ji

**IP10-5** Management of chemotherapy-induced nausea and vomiting and adherence to antiemetic guidelines from perspectives of doctors in Beijing

Day Oncology Unit, Peking University Cancer Hospital, China Wang Yanfei

**IP10-6** Descriptive Study on the Quality of Life Among the Caregivers of Cancer Patients undergoing Out-patient Chemotherapy in Cancer Care Center of Medical Center Manila (ManilaMed)

Medical Oncology, Augusto P. Sarmiento Cancer Institute - The Medical City, Philippines Alfred Patrick D. Mina

**IP10-7** Predictive Model for Assessing Malnutrition in Elderly Hospitalized Cancer Patients: A Machine Learning Investigation

Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, China Ran Duan

## International Poster 11

Saturday, October 26 13:30~14:15

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Upper GI (Esophagus)

Chair : Koji Shindo Department of Surgery and Oncology, Kyushu University

**IP11-1** Predicting anastomotic leak in patients with esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy using a nomogram based on CT radiomic and clinicopathologic factors

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China Junfeng Zhao

**IP11-2** Neoadjuvant Chemotherapy Combined with Camrelizumab for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Cohort Study

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China Yueyun Chen

**IP11-3** Inflatable mediastinoscopy-assisted modified-Mckeown esophagectomy (im-Mckeown) in patients with esophageal cancer combined with left lung disease

Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, China Zhang Guoqing

**IP11-4** Textbook outcome is a valid comprehensive assessment tool for surgical quality of esophagectomy: a national cohort study of China

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China Gao Yushun

**IP11-5** Artificial intelligence-based preoperative precision assessment of thoracic esophageal cancer staging by CT radiomics and clinical features

Department of Radiation Oncology, Weifang People's Hospital, China Geng Xiaotao

**IP11-6** Positive Tumor-informed Margin with TP53 Mutations Indicates Poor Surgical Outcomes in Esophageal Squamous Cell Carcinoma Patients: A Single-center Retrospective Cohort Study

Department of Thoracic Surgery, Southern Medical University, China Di Lu

## International Poster 12

Saturday, October 26 13:30~14:20

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Upper GI (Stomach)

Chair : Yoshihiko Kakiuchi Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Science

**IP12-1** Report, Treatment, and Prognostic Analysis of 10 Cases of Multiple Primary Cancers

Gastro-Oncology, Gansu Hospital, Sun-Sat-sen University Cancer Hospital, China Zhihu Z. Li

**IP12-2** Clinicopathologic characteristics and prognostic factors of gastric cancer patients with low and high tumor budding in Vietnam

Medical Oncology No. 6, Vietnam National Cancer Hospital, Vietnam Thi Hoai Hoang

**IP12-3** Prognostic Immune and Nutritional Index as a Predictor of Survival in Patients Undergoing Curative-intent Resection for Gastric Cancer

Medical Oncology/Hematology, Internal Medicine, Kyung Hee University Hospital at Gangdong, Korea Wankyu Eo

**IP12-4** Identification of Prognostic Signatures in Remnant Gastric Cancer through an interpretable risk model based on machine learning: A multicenter cohort study

Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, China Zhouwei Zhan

---

**IP12-5** A case of neoadjuvant chemotherapy in the treatment of dual primary malignant tumours of the stomach and rectum

Department of Gastrointestinal Surgery, Surgery, Shanghai East Hospital, Tongji University, China Renhao Hu

**IP12-6** Using Neoadjuvant Chemotherapy in combination with Antiangiogenesis and Immune Checkpoint Inhibitors to Treat Locally Advanced Gastric Cancer: A Real-World Retrospective Cohort Study

Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, China Zhouwei Zhan

**IP12-7** A novel artificial intelligence-based system can be a useful assistant for real-time blind spots monitoring and quality improvement during EGD: a multicenter randomized controlled study

Endoscopy, Zhejiang Cancer Hospital, China Yandong Li

### International Poster 13

Saturday, October 26 13:30~14:30

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Upper GI (Basic)

Chair : Masaaki Iwatsuki Department of Gastroenterological Surgery, Kumamoto University

**IP13-1** A pyroptosis score-based model for prognosis prediction of esophageal squamous cell carcinoma

Department of Oncology Radiationtherapy, Nanjing Medical University Affiliated Changzhou Second People's Hospital, China Jianlin Wang

**IP13-2** The expression of JUN, STUB1, FBXL5, and SNRPE after radiotherapy is prognostic in patients with esophageal cancer

Department of Oncology Radiationtherapy, Nanjing Medical University Affiliated Changzhou Second People's Hospital, China Jianlin Wang

**IP13-3** High Expression of NF1 in Human Esophageal Squamous Cell Carcinoma Correlates with Tumor Metastasis and Poor Prognosis

Department of Thoracic Cancer Center, Chongqing University Cancer Hospital, China Dongming Guo

**IP13-4** APLN Overexpression Promotes Proliferation and Angiogenesis of Gastric Cancer cells

Department of Oncology, Binzhou Medical University Hospital, China Li-Jun Tian



**IP13-5** The role and mechanism of FTO mediated m6A modification regulating circNFATC3/miR-23b-3p in RAI14-induced gastric cancer development

Department of Geriatric 1, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, China Xinxin Yan

**IP13-6** HMGB1 as a Potential Predictive Biomarker in Immune Checkpoint Inhibitor plus Cytotoxic Chemotherapy for Gastric Cancer

Internal Medicine, The Catholic University of Korea, Seoul St Mary's Hospital, Korea Seunghan Kim

**IP13-7** TREM2 inhibits proliferation by promoting apoptosis and pyroptosis of gastric cancer

Oncology Department, The First Hospital of Lanzhou University, China Chun Mei Li

**IP13-8** Targeting Antigen-Presenting Cells to Enhance the Tumor-Spleen Immunity Cycle through Liposome-Neoantigen Vaccine

Department of Medical Oncology, Sun Yat-sen University Cancer Center, China/ Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, China Yu Xu

## International Poster 14

Saturday, October 26 13:30~14:30

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Colorectal (Clinical)

Chair : Mitsuru Ishizuka Department of Colorectal Surgery, Dokkyo Medical University

**IP14-1** Nomograms integrating the collagen signature and systemic immune-inflammation index for predicting prognosis in non-pathological complete response rectal cancer patients

Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China Xian Yu

**IP14-2** Association between serum lipids and colorectal cancer: a propensity score matching analysis

Department of Gastrointestinal Surgery, Surgery, Shanghai East Hospital, Tongji University, China Renhao Hu

**IP14-3** Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial

Colorectal Surgery, Department of Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, China Jinlin J. Cai

- 
- IP14-4** Preliminary Efficacy and Safety of Total Neoadjuvant Therapy Combined with PD-L1 Blockade in pMMR/MSS Locally Advanced Rectal Cancer (ESTIMATE): A Prospective, Single-Arm, Phase II Trial  
Department of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, China Xuan Zhang
- IP14-5** Laparoscopic approach in the surgical treatment of a large retrorectal tumor: a rare case series  
Division of Colorectal Surgery, Department of Surgery, Chonnam National University Hospital, Korea Jae Kyun Ju
- IP14-6** Effect of Prognostic Nutritional Index on Laboratory Parameters and Survival in Patients With Metastatic Colorectal Cancer Treated With Fruquintinib  
Department of Pharmacy, Zhejiang Cancer Hospital, China Wang Zeng
- IP14-7** Research on the effect of RC48-ADC in HER2-positive colorectal cancer  
Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, China Yuwei Ding
- IP14-8** Real-world treatment patterns and clinical outcomes for immunotherapy-based regimens in patients with MSS metastatic colorectal cancer  
Cancer Center, Department of Oncology, Renmin Hospital of Wuhan University, China Wensi Zhao

## International Poster 15

Saturday, October 26 13:30~14:05

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Colorectal (Basic)

Chair : Keitaro Shimozaki Cancer Institute Hospital of Japanese Foundation for Cancer Research

- IP15-1** Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer  
Colorectal Surgery, Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, China/State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, China Rong-Xin Zhang
- IP15-2** Suppression of the development and progression of colon cancer by ezetimibe and shRNA-mediated inhibition of NPC1L1  
Department of Family Medicine, Pusan National University Yangsan Hospital, Korea Soo Min Son

---

**IP15-3** Transcription factor ONECUT3 regulates HDAC6/HI-1a activity to promote the Warburg effect and tumor growth in colorectal cancer

Department of Oncology, Shanghai East Hospital, China/School of Medicine, Tongji University, China Weihan Li

**IP15-4** The bioinformatics and experimental analysis of CD276 for prognosis and immune infiltrates in colon adenocarcinoma

Department of Oncology, First Hospital of Lanzhou University, China Chen Rui

**IP15-5** Investigating the FABP4/UCP2 Axis in Cetuximab Resistance: Implications for Obesity-Linked Colorectal Cancer

Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan/Division of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taiwan Yi-Chiao Cheng

## International Poster 16

Saturday, October 26 13:30~14:05

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Liver (Surgery)

Chair : Masamichi Hayashi Nagoya University, Department of Surgery (HBPS)

**IP16-1** Multidisciplinary clinical discussion of a patient with Hepatic perivascular epithelioid cell tumor

Oncology Department, The First Affiliated Hospital of Chongqing Medical University, China Huimin Du

**IP16-2** Enhanced CT-Based Radiomics Prediction Model for the Prognosis of Advanced Intrahepatic Cholangiocarcinoma Patients Receiving Immunotherapy Combined with Chemotherapy

Department of Hepato-Pancreato-Biliary Centers, Zhong Da Hospital, School of Medicine, Southeast University, China Xuwu Tang

**IP16-3** Nomogram Based on Tumor Burden Score Predicting Prognosis for Patients with Hepatocellular Carcinoma after Hepatectomy

Department of Hepato-Pancreato-Biliary Centers, Zhong Da Hospital, School of Medicine, Southeast University, China Weihu Ma

**IP16-4** Efficacy and safety analysis of TACE plus donafenib with or without PD-1 for unresectable hepatocellular carcinoma: a prospective, single-arm, single-center, phase II clinical study

Ward 1, Interventional Therapy Department, Shandong Cancer Hospital and Institute, China Jinpeng Li

---

**IP16-5** Efficacy and safety of TACE combined with regorafenib and PD-1 inhibitor in the treatment of hepatocellular carcinoma after first-line treatment failure

Ward 1, Interventional Therapy Department, Shandong Cancer Hospital and Institute, China Jinpeng Li

### International Poster 17

Saturday, October 26 13:30~14:05

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Liver (Radiation)

Chair : Katsuyuki Sakanaka Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University

**IP17-1** Risk factors and predictive analysis of acute severe abdominal pain after hepatic artery infusion chemotherapy

Ward 1, Interventional Therapy Department, Shandong Cancer Hospital and Institute, China Jinpeng Li

**IP17-2** Magnesium Microspheres to Enhance Lipiodol-mediated Transarterial Chemo-Embolization (TACE) of Hepatocellular Carcinoma: from Bench to a Pilot Clinical Study

Department of Oncology Center, The Fifth Affiliated Hospital of Wenzhou Medical University, China Liyun L. Zheng

**IP17-3** Withdrawn

**IP17-4** Could the combination of radiotherapy with anti-angiogenic therapy and immunotherapy emerge as the standard treatment for hepatocellular carcinoma patients with portal vein tumor thrombosis?

Radiotherapy Department, The First Hospital of Jilin University, China Lijuan Ding

**IP17-5** The management of shunt dysfunction caused by stent deviation during transjugular intrahepatic portosystemic shunt surgery for esophageal and gastric varices bleeding

Department of Interventional Catheter Therapy, Heping Hospital Affiliated to Changzhi Medical College, China Jinmao Chen

## International Poster 18

Saturday, October 26 13:30~14:20

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Liver (Clinical, Basic)

Chair : Hideki Yokoo Division of HBP and Transplant Surgery, Department of Surgery, Asahikawa Medical University

**IP18-1** Clinical and pathologic features of dual phenotype of hepatocellular carcinoma, a novel subtype of hepatocellular carcinoma

Hepatic-Biliary-Pancreatic Cancer Department, Nanjing Tianyinshan Hospital, China  
Pharmaceutical University, China/Department of Medical Oncology Center, Jinling  
Hospital, Nanjing University School of Medicine, China Chen Xun

**IP18-2** Patients with microvascular invasion after hepatocellular carcinoma resection, early adjuvant Transcatheter arterial Chemoembolization

Infectious Disease, The First Affiliated Hospital of Soochow University, China  
Yunhai Yao

**IP18-3** Efficacy and Safety of Low-Dose Cyclophosphamide Combined with Lenvatinib, Pembrolizumab, and TACE for Unresectable Hepatocellular Carcinoma: A Single-Center, Prospective, Single-Arm Clinical Trial

Hepatobiliary & Pancreas Surgery, Lingnan Hospital, The Third Affiliated Hospital of  
Sun Yat-Sen University, China Zhicheng Yao

**IP18-4** Complete Pathological Response in Advanced Hepatocellular Carcinoma. Be Brave

Oncology, Centro Hospitalar Conde de São Januário, Macao Ingrid K. Sumou

**IP18-5** Pancreatobiliary reflux induces macrophage-secreted IL-8 and activates the PI3K/NFkB pathway to promote cholangiocarcinoma progression

The Affiliated Hospital of Qingdao University, China Tingting Wu

**IP18-6** Gut microbiota mediates the protective effects of Resveratrol against the intestinal barrier dysfunction in non-alcoholic steatohepatitis induced by high-fat diet

Department of Clinical Nutrition, Chongqing University Cancer Hospital, China  
Mengting Chen

**IP18-7** Clathrin light chain A-enriched small extracellular vesicles remodel microvascular niche to induce hepatocellular carcinoma metastasis

Hepatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University,  
China Yi Xu

## International Poster 19

Saturday, October 26 13:30~14:00

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Gallbladder / Biliary Tract

Chair : Masafumi Ikeda National Cancer Center Hospital East

**IP19-1** A New TNM T3 Subclassification with Corresponding Prognostic Stage Grouping for Gallbladder Cancer: a Multicenter Retrospective Study

Hepatobiliary and Pancreatic Center, Zhongda Hospital, Southeast University, China

Facai Yang

**IP19-2** The Synergistic Effect of Kaempferol and BAY-876 Targeting Ferroptosis in ICC

Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Department of Medical Oncology, Cancer Institute, The Second Affiliated Hospital of

Zhejiang University, School of Medicine, China Yan Zhang

**IP19-3** Efficacy and Safety of Camrelizumab, Apatinib, and Capecitabine Combination Therapy in Advanced Biliary Tract Cancer: A Phase 2, Single-arm Prospective Study

General Surgery, Beijing Friendship Hospital, Capital Medical University, China

Chao Jing

**IP19-4** Comparison of clinical outcomes for adjuvant chemoradiation versus adjuvant chemotherapy following resection biliary tract cancer, A retrospective cohort study

Medical Oncology Unit, Department of Internal Medicine, Khon Kaen Cancer Center,

Khon Kaen Hospital, Thailand Luangyot Thongthieang

## International Poster 20

Saturday, October 26 13:30~14:20

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Pancreas

Chair : Yasushi Kojima National Center for Global Health and Medicine

**IP20-1** Mechanism and translational research on the activation of DDR1/IRS4 pathway mediated by TM4SF20 to promote pancreatic cancer metastasis

Tianjin, Pain Management, Tianjin Cancer Hospital, China Liu Weishuai

**IP20-2** Role of eustress-microbiota-Th17/Treg axis in the anti-pancreatic cancer immunity: a mechanistic study

Oncology Department and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong

University, China Yiyi Liang

**IP20-3** Early Detection of Pancreatic Cancer Using *C. elegans*

Shonan R&D Center, Hirotsu Bio Science Inc. Umbhorn Ungkulpasvich

**IP20-4** Application of bacterial carrier nanodrug delivery system in chemotherapy resistance of pancreatic cancer and regulation of tumor microenvironment

Oncology Department and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China Yiyi Liang

**IP20-5** Study of the biological activity of proteolysis-targeting chimeras (PROTAC) targeting Kras-G12D LT-010136 and its molecular mechanism in solid tumors

Oncology, Shanghai East Hospital, China Gao Yuan

**IP20-6** Nimotuzumab Plus Chemotherapy for KRAS Wild-Type Advanced Pancreatic Cancer - A Single Center Experience

Department of Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, China Li Xiao

**IP20-7** Chemotherapy and sequential radiotherapy are effective and safe for locally advanced pancreatic cancer patients age 65 and over

Radiation Oncology, The First Hospital of Jilin University, China Lijuan Ding

## International Poster 21

Saturday, October 26 13:30~14:20

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Head and Neck / Thyroid

Chair : Ryuji Yasumatsu Department of ORL-Head Neck Surgery, Kindai University

**IP21-1** 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Nasopharyngeal Carcinoma

Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, China Bijuan Chen

**IP21-2** Prognostic Values of Pretreatment Asymmetric Dimethylarginine in Predicting Distant Metastasis in Patients with Nasopharyngeal Carcinoma

Department of Oncology, Third Xiangya Hospital of Central South University, China Qing Nan Tang

**IP21-3** Microwave ablation versus surgical resection for solitary cT1N0M0 papillary thyroid carcinoma: a prospective multi-center study

Department of Interventional Ultrasound, Chinese PLA General Hospital Fifth Medical Center, China Qiaowei Du

**IP21-4** Microwave ablation for T1N0M0 papillary thyroid carcinoma located in isthmus and lateral lobes: A multicenter prospective cohort study

Department of Interventional Ultrasound, Chinese PLA General Hospital Fifth Medical Center, China Lin Zheng

**IP21-5** Allogeneic Aortic Transplantation with Stem Cell-Seeded Photocurable Stents for Long-Segment Airway Reconstruction in Rat Models

Thoracic Surgery, General Surgery Center, The First Hospital of Jilin University, China/Transplantation Center, General Surgery Center, The First Hospital of Jilin University, China Shixiong Wei

**IP21-6** Clinical features, management and prognostic factors of patients with mucosa-associated lymphoid tissue lymphoma of parotid gland

Department of Medical Oncology, Fudan University Shanghai Cancer Center, China Yizhen Liu

**IP21-7** Pathological diagnosis and prognostic significance of squamous cell components in papillary thyroid carcinoma

Pathology, Peking University Cancer Hospital, China Yanhua Bai

## International Poster 22

Saturday, October 26 13:30~14:15

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Breast (Thearpy 1)

Chair : Tatsuya Toyama Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences

**IP22-1** A prospective, open, single-arm clinical trial of the effect of rice bran arabinoxylan (MGN-3) on immune function in patients with breast and colorectal cancer

Department of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, China/Tongji University Cancer Center, China Huaxin Zhao

**IP22-2** Denosumab versus zoledronic acid for the treatment of bone metastasis in breast cancer patients: a propensity score matched cohort study

Division of Breast Cancer, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, China Xiang Huang

**IP22-3** Malignant phyllodes tumor of breast with ulceration in a young woman a case report

General Surgery Department, Huidong County People's Hospital, Jinan University, China Tianjian L. Lu



**IP22-4** Assessment of Survival Outcomes in Elderly Patients with HER2-Negative Breast Cancer Following Neoadjuvant Chemotherapy: A Population-Based Cohort Study

Department of Breast Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, China Lv Wenjie

**IP22-5** Real-World Treatment Patterns and Clinical Outcomes of Eribulin in Her-2 negative metastatic breast cancer patients with PI3K pathway alterations

Breast Medical Oncology, Zhejiang Cancer Hospital, China Huanhuan Zhou

**IP22-6** Pneumocystis jirovecii Pneumonia infection in three Breast Cancer patients receiving Dose-dense Chemotherapy: A Case Report and Literature Review

Medical Oncology, Augusto P. Sarmiento Cancer Institute - The Medical City, Philippines Alfred Patrick D. Mina

## International Poster 23

Saturday, October 26 13:30~14:20

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Breast (Thearpy 2)

Chair : Hiromitsu Jinno Department of Surgery, Teikyo University School of Medicine

**IP23-1** A phase II study of neoadjuvant dalpiciclib plus letrozole, trastuzumab, and pertuzumab for HR+/HER2+ breast cancer

Department of Breast Cancer, Chongqing University Cancer Hospital, China Liang Xinrui

**IP23-2** The mechanism of acidic microenvironment promotes tumor-associated macrophages secreting glutamine to activate dual signaling pathways in CDK4/6 inhibitor resistance of ER-positive breast cancer

Department of Breast Cancer Center, Chongqing University Cancer Hospital, China Fanli Qu

**IP23-3** Targeting FBXL20 to reverse HER2-positive breast cancer resistance to trastuzumab by regulating HER2 internalization

Breast Cancer Center, Chongqing Cancer Hospital, Chongqing University, China Guanwen Wang

**IP23-4** m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancer

Breast Cancer, Oncology, The First Affiliated Hospital of Nanjing Medical University, China Fan Yang

**IP23-5 Outcomes of Postoperative Radiotherapy in Male Breast Cancer Patients: A Population-based Analysis**

Department of Radiation Oncology, The First Affiliated Hospital of Medical School of Zhejiang University, China Xin Sun

**IP23-6 Neoadjuvant therapy for dual breast cancer (triple positive and triple negative): a case report and comprehensive literature review**

Department of Breast Surgery, Heping Hospital Affiliated to Changzhi Medical College, China Wenwen Dong

**IP23-7 HER2 breast cancer with brain metastases and Li-Fraumeni syndrome**

Oncology, Centro Hospitalar Conde de São Januário, Macao Ingrid K. Sumou

**International Poster 24**

Saturday, October 26 13:30~14:30

Poster Room (Arena, 1F, Marine Messe Fukuoka)

**Breast (Clinical)**

Chair : Tomoharu Sugie Kansai Medical University Kori Hospital Outpatient Chemotherapy Center

**IP24-1 2'-Fucosyllactose Alleviates 5-FU Induced Small Intestinal Mucositis Through Gut Microbiota and SCFAs**

Breast Cancer Oncology Department, Tianjin Cancer Hospital Airport Hospital, China/Breast Cancer Oncology Department, Tianjin Medical University Cancer Institute & Hospital, China Xiaochen Jia

**IP24-2 Factors associated with sedentary behavior among community-dwelling breast cancer survivors**

Department of Rehabilitation Medicine, College of Medicine, The Catholic University of Korea, Korea Kim Yeo Hyung

**IP24-3 The correlation between elevated resting heart rate and physical fitness assessed by 6-minute walk test (6MWT), and their prognostic values in patients with breast cancer**

Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital, Indonesia Yufi K. Astari

**IP24-4 Research Progress on the Alleviating Effect of Probiotics on Post-chemotherapy Depression in Breast Cancer**

Medical Oncology, Cancer Center, Inner Mongolia People's Hospital, China Zhihui Cai

**IP24-5 Predictive model of prognosis index for invasive micropapillary carcinoma of the breast based on machine learning: A SEER population-based study**

Breast Surgery, Clinical Oncology School of Fujian Medical University, China/Thyroid and Breast Surgery, Ningde Municipal Hospital of Ningde Normal University, China Zirong Jiang

**IP24-6** Differences and correlation analysis between baseline stress hormone levels and CD4+ and CD8+ T cell counts in benign and malignant breast lesions

Medical, Oncology, Zhongda Hospital Affiliated to Southeast University, China  
Shiya Zheng

**IP24-7** A multichannel nanosensor based on molecular characterization of exosomes for subtype-based diagnosis of breast cancer

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, China Zeng Tianyu

**IP24-8** Local Experience on Radioguided Occult Lesion Localization (ROLL) for Non-Palpable Breast Lesions: A Single-Center Case Series

Nuclear Medicine and PET/CT Center, The Medical City, Philippines  
Rey Alfred E. Inting

## International Poster 25

Saturday, October 26 13:30~14:30

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Breast (Basic 1)

Chair : Ken-Ichi Ito Division of Breast & Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine

**IP25-1** Exosomal circRNA RHOT1 Promotes Breast Cancer Progression by Targeting miR-204-5p/ PRMT5 axis

Department of Breast Surgery, The Tumor Affiliated Hospital, Xinjiang Medical University, China Weihua Jiang

**IP25-2** ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation

Clinical Medicine, Oncology, The Affiliated Hospital of Southwest Medical University, China Yu Fan

**IP25-3** Mendelian Randomization and Bayesian Weighted Algorithm Reveal the Clinical Implications of Transcriptome-Modulated Alternative Splicing in Nuclear Receptor-Related Signaling: A Retrospective Study

Surgical Oncology, Taizhou Central Hospital (Affiliated Hospital of Taizhou University), China Zhe Hu

**IP25-4** Deubiquitinating enzyme USPX stabilizes EGRX to promotes proliferation and migration of breast cancer cells

Breast Surgery, Yunnan Cancer Hospital, China Zhen Li

**IP25-5** EDIL3+CAF DISRUPT THE INTER-CELLULAR TIGHT JUNCTIONS OF LYMPHATIC ENDOTHELIAL CELLS TO PROMOTE LYMPH NODE METASTASIS IN BREAST CANCER

Breast Surgery, Second Affiliated Hospital, Medical School, Zhejiang University, China Ni Chao

**IP25-6** Myeloid PTEN loss affects therapeutic response by promoting stress granules assembly and impairing phagocytosis of macrophages in breast cancer

Department of Medical Oncology, The First Affiliated Hospital of USTC (University of Science and Technology of China), China/Division of Life Sciences and Medicine, University of Science and Technology of China, China Yan Li

**IP25-7** Targeting UCH37 inhibits PD-L1 proteasomal degradation and induces immunogenic cell death in triple-negative breast cancer

Breast and Thyroid Surgery, Women and Children's Hospital of Chongqing Medical University, China Xiao Qian

**IP25-8** RAB5A-mediated TNBC-TAMs interaction affects macrophage phenotypic reprogramming and malignant mechanism of TNBC breast cancer in triple negative breast cancer

Department of Breast and Thyroid Surgery, Xinjiang Medical University Affiliated Tumor Hospital, China Lei Qiao

## International Poster 26

Saturday, October 26 13:30~14:15

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Breast (Basic 2)

Chair : Yuko Takahashi Breast and Endocrine Surgery, Okayama University Hospital

**IP26-1** SEMA7A as a Novel Prognostic Biomarker and Its Correlation With Immune Infiltrates in Breast Cancer

Hebei, Department of Breast Surgery, Xingtai People's Hospital, China Lixian Yang

**IP26-2** Integrative analysis of the cell cycle inhibitor, p27 (CDKN1B) in breast cancer: Implications for Prognosis and Therapeutic Strategies

Department of Pathology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Korea Kyueng-Wan Min

**IP26-3** Targeting PANX1 to Sensitize Breast Cancer Cells for Doxorubicin Treatment via Inflammasome Activation

Breast Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, China Chenxuan Yang

**IP26-4** Multiomics-based molecular subtyping of the commensal microbiome predicts molecular characteristics and therapeutic response in breast cancer

Department of Medical Oncology, Fudan University Shanghai Cancer Center, China  
Wenxing Qin

**IP26-5** Evaluation of the Large Language Model on Breast cancer-related lymphedema and Its Efficacy in Cancer Research: A Case Study

Surgery, Anshan Cancer Hospital, China Zhaoduo Jin

**IP26-6** A MACHINE LEARNING MODEL FOR THE PREDICTION OF ESTROGEN RECEPTOR EXPRESSION USING F-18 FDG PET/MR IN PATIENTS OF BREAST CANCER

Department of Nuclear Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Korea Bong Il Song

## International Poster 27

Saturday, October 26 13:30~14:05

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Uterus 1

Chair : Yoshihito Yokoyama Department of Obstetrics and Gynecology, Hirosaki University

**IP27-1** EphA2 promotes the development of cervical cancer by regulating tumor-associated macrophages

Department of Obstetrics and Gynecology, The Third Affiliate Hospital of Zhengzhou University, China Qian Li

**IP27-2** Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T-cell senescence and cervical cancer recurrence

The Affiliated Cancer Hospital of Nanjing Medical University, China  
Dongfang Dai

**IP27-3** Examination of the Functions and Mechanism of KCP in Mediating Paclitaxel Resistance in Cervical Squamous Carcinoma Cells

Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, China  
Yue He

**IP27-4** A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer

Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, China Haifeng Qiu

**IP27-5** A prospective single-arm phase 2 study of dual isocenters MR-guided adaptive radiotherapy for gynecological tumors: Early toxicity results

First Ward of Uterine Tumor, Shandong Cancer Hospital, China Cong Wang

## International Poster 28

Saturday, October 26 13:30~14:15

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Uterus 2

Chair : Ken Yamaguchi Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University

**IP28-1** To assess the association of treatment risk with peritoneal suture in patients with postoperative concurrent chemoradiotherapy for cervical cancer and endometrial cancer

First Ward of Uterine Tumor, Shandong Cancer Hospital, China Cong Wang

**IP28-2** Clinical study of granulocyte macrophage colony-stimulating factor (GM-CSF) combined with chemoradiotherapy for the treatment of recurrent cervical cancer

Department of Gynecologic Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China  
Na Zhang

**IP28-3** Durvalumab in Combination with concurrent chemoradiation and Adjuvant Therapy for Cervical Cancer in 2018 FIGO Stage III

Department of Gynecologic Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China  
Na Zhang

**IP28-4** The intra-tumoral microbiome as a potential biomarker of response to external beam radiation therapy in cervical cancer

Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, China Lan Zhang

**IP28-5** Effectiveness of consolidation chemotherapy after concurrent chemoradiation in high-risk early-stage cervical cancer patients following radical hysterectomy

Department of Radiation Oncology, Qilu Hospital of Shandong University, China  
Zhang Guangyu

**IP28-6** ZBTB5 enhances the resistance of cervical cancer to paclitaxel by regulating BCL6

Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, China  
Yue He

## International Poster 29

Saturday, October 26 13:30~14:30

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Ovary

Chair : Eiji Kondo Mie University, Department of Obstetrics and Gynecology

**IP29-1** CDC42, a novel cancer stem cell-related biomarker, is a therapeutic target for ovarian cancer

Department of Gynecology, The First Affiliated Hospital of Sun Yat-sen University,  
China Ming Chen

**IP29-2** Mechanism of SIRT5 in regulating invasion metastasis and glycolysis of ovarian cancer cells

Gynecologic Oncology, Jilin Cancer Hospital, China/Postdoctoral Research  
Workstation, Jilin Cancer Hospital, China Sun Xiaodan

**IP29-3** Exhaustive capture of infertility and ovarian cancer linkage integrating canonical and alignment-free protocols

Department of Gynecology and Obstetrics, The First Affiliated Hospital, Zhejiang  
University School of Medicine, China Zhiqin Fu

**IP29-4** Serum level of WT1 gene in the diagnosis of ovarian cancer

Lab Oncology, Cancer Hospital, All India Institute of Medical Sciences, India  
Harshita Dubey

**IP29-5** Should serum level WT1 gene correlate with its tissue expression in cancer patient?

Lab Oncology, Cancer Hospital, All India Institute of Medical Sciences, India  
Amar Ranjan

**IP29-6** Survival Outcomes of Patients with Ovarian Cancer Undergoing Secondary Cytoreduction at First versus Second Platinum-Sensitive Recurrence: A Multicenter Retrospective Cohort Study

Department of Gynecologic Oncology, National Cancer Center/National Clinical  
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences  
and Peking Union Medical College, China Yuxi Zhao

**IP29-7** Effects of neoadjuvant chemotherapy on prognosis and platinum resistance of advanced ovarian cancer

Gynecologic Cancer Center, Cancer Hospital of China Medical University, Liaoning  
Cancer Hospital and Institute Shenyang, China Weishan Li

**IP29-8** Clinicopathological characteristics of ovarian clear cell carcinoma and treatment of recurrent cases: a single-center analysis of 247 cases in China

Gynecology Oncology, National Cancer Center/National Clinical Research Center for  
Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union  
Medical College, China You Wu

## International Poster 30

Saturday, October 26 13:30~14:20

Poster Room (Arena, 1F, Marine Messe Fukuoka)

### Basic Science

Chair : Toshiaki Ohara Pathology & Experimental Medicine, Okayama University

**IP30-1** NTN4/ITGB4 cooperates with EGF/EGFR to protect glioblastoma cells from temozolomide induced senescence

Department of Oncology, The Second Hospital Affiliated to Harbin Medical University, China Li Li

**IP30-2** Application of the Ruanjian-sanjie capsule as anti-glioma agents

Department of Oncology, Shanxi Province Academy of Traditional Chinese Medicine, Shanxi Province Hospital of Traditional Chinese Medicine, China Jing Zhou

**IP30-3** METASTASIS-ENHANCING PROTEIN KITENIN CONFERS TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA WITH UNMETHYLATED MGMT VIA UPREGULATION OF CANCER STEM CELL MAKERS

Neuropathology, Department of Pathology, Chonnam National University Medical School, Korea Jaehyuk Lee

**IP30-4** ADAM15 is a potential biomarker for pan-cancer prognosis and immunotherapy

Clinical Laboratory Science, Tongji University, China Wenjia Guo

**IP30-5** Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy

Department of Medical Oncology, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, China Youchao Y. Jia

**IP30-6** Global research trends of tumor-associated fibroblasts in cancer: A bibliometric and visualized analysis study over past 20 years

Medical Oncology, Department of Medical Oncology, The First Hospital of China Medical University, China Wang Jin

**IP30-7** A novel MCT-4 inhibitor increases taxanes efficacy in taxane-resistant cancer cells by downregulation of ABCB1

Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, China/Tongji University School of Medicine, China Xiaofan Duan



## Luncheon Seminar 5

Thursday, October 24 12:30~13:30

Room 5 (204, 2F, Fukuoka International Congress Center)

Co-sponsored : MIYARISAN PHARMACEUTICAL CO., LTD

Chair : Yuji Toiyama Department of Gastrointestinal and Pediatric Surgery  
Mie University Graduate School of Medicine

### Current Status and Prospects of Perioperative Treatment for Rectal Cancer

Department of Colorectal Surgery, Kansai Medical University Jun Watanabe

### Circulating nucleic acid markers in pancreatic cancer

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman  
Research Institute of City of Hope Comprehensive Cancer Center Ajay Goel

## Luncheon Seminar 22

Friday, October 25 11:50~12:50

Room 5 (204, 2F, Fukuoka International Congress Center)

Co-sponsored : MSD K.K.

### Multidisciplinary treatment for esophageal cancer

Chair : Hiroya Takeuchi Hamamatsu University School of Medicine, Department of Surgery

Dept. of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, USA  
Wayne L Hofstetter

## Luncheon Seminar 28

Friday, October 25 11:50~12:50

Room 11 (501, 5F, Fukuoka International Congress Center)

Co-sponsored : Oncolys BioPharma Inc.

### New Era of Immuno-Oncology - Cutting Edge of Immunotherapy with Oncolytic Viruses -

Chair : Hisahiro Matsubara Department of Frontier Surgery, Graduate School of Medicine,  
Chiba University, Chiba, Japan

National Cancer Center Research Institute, Tokyo, Japan Kazunori Aoki  
Division of Hematology and Medical Oncology, Weill Cornell Medical College,  
New York City, NY, USA Manish A. Shah